Author's posts
Focus Needed Not Just On Drugs But Hospital Expenses To Impact Healthcare Costs
Despite the fact that hospital costs are the biggest part of our health care system and that such costs are growing more rapidly than other health care segments, politicians find it easier to go after biopharma companies.
ProPublica Is Way Off Base With Its Analysis Of Pharma Payments To Doctors
It’s great that ProPublica generates these data. The transparency it provides is important for the debate on healthcare spending. However, let’s not sensationalize the results at the expense of the pharmaceutical industry.
Vioxx, Once Vilified Like Thalidomide, May Also Return To The Market
Obviously, the FDA would want to be certain that the benefit for using Vioxx in hemophilic arthropathy outweighed the attendant risk before allowing Vioxx (rofecoxib) to be reintroduced to the marketplace.
The Real Impact Of Drug Price Legislation On Biopharmaceutical R & D
A 10% budget cut in R&D across the board for the biopharmaceutical industry would be felt not just in the U.S. but around the world.
Why Do Post-Marketing Drug Studies Required By The FDA Take So Long?
These type of delays reflect badly on both the FDA and drug companies, the former because it seems that the agency is not doing its job and the latter because it appears that companies are intentionally shirking their responsibilities to avoid finding …
Why Do Post-Marketing Drug Studies Required By The FDA Take So Long?
These type of delays reflect badly on both the FDA and drug companies, the former because it seems that the agency is not doing its job and the latter because it appears that companies are intentionally shirking their responsibilities to avoid finding …
Suicide Risk For Restless Legs Syndrome Patients
Given the increasing incidence of suicide in the U.S., it is imperative that RLS patients be treated rigorously and their health issues not be dismissed.
The Medicines Company Trumpets New Inclisiran Cholesterol Lowering Results, But Big Questions Remain
He is right on the money, so to speak. MDCO might get there with inclisiran, but the current data aren’t yet supportive of changing CV medical practice.
Novartis Delayed Reveal Of Bad Data For $2.1 Million Gene Therapy. Now Patients And Pharma Suffer.
Narasimhan’s poor decision making has had negative consequences not just for Novartis but also for the industry and patients. Let’s hope it’s not repeated.
Regeneron’s Great Science Led To An Important Drug. But Will It Flop Commercially?
Great science doesn’t always generate great returns.
